Evidence map›Paper›PMID 40923250›Full record

ArticleTherapeutic delivery2025

Exploring the hypoglycemic potential of HuGLP-1-loaded bilosomes in controlling type 2 diabetes mellitus.

Mayur Kedarnath Vidhate, Shyam Sudhakar Gomte, Naveen Singh, Dimpal Suthar, Aakanchha Jain

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mayur Kedarnath VidhateDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Gandhinagar, India.
Shyam Sudhakar GomteDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Gandhinagar, India.
Naveen SinghDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Gandhinagar, India.
Dimpal SutharDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Gandhinagar, India.
Aakanchha JainDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Gandhinagar, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (T2DM) is the most devastating disease and it necessitates therapeutic intervention for its effective management. Human Glucagon-like peptide-1 (HuGLP-1) is the potential candidate in the treatment of T2DM; however, it limits its utilization owing to its solubility and stability issues.

aimsThe current investigation aims to develop HuGLP-1-loaded bilosomes as a novel strategy for managing T2DM. MATERIALS AND

methodsThe HuGLP-1-loaded bilosomes were developed and characterized for its size, polydispersity index, surface charge, entrapment efficiency, morphology, drug release, and stability studies. The hypoglycemic potential and histopathology were studied using streptozotocin-induced diabetic rats.

resultsBilosomes were successfully developed with size of 197.96 ± 0.61 nm, polydispersity index 0.191 ± 0.01 and surface charge of -27.63 ± 1.02 mV. The in vitro release of HuGLP-1-loaded bilosomes showed sustained release profile of HuGLP-1 extending over 24-h period, in compared to plain HuGLP-1 solution, and follows Weibull release kinetics model. The HuGLP-1-loaded bilosomes revealed significant hypoglycemic effects in comparison to both oral and subcutaneous HuGLP-1 solutions. Histopathological evaluations revealed that HuGLP-1-loaded bilosomes showed promising improvement in histology of liver, kidney, and intestines.

conclusionThe HuGLP-1-loaded bilosomes were found to be potential therapeutic approach for the effective management of T2DM.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Glucagon-Like Peptide 1Hypoglycemic AgentsAnimalsBlood GlucoseDelayed-Action PreparationsDrug LiberationHumansMaleParticle SizeRatsRats, Sprague-DawleyStreptozocinBlood GlucoseDelayed-Action PreparationsGlucagon-Like Peptide 1Hypoglycemic AgentsStreptozocinantidiabeticbilosomesDiabetes mellitusdrug deliveryhuman glucagon like peptide-1

Identifiers

PMID40923250
PMCPMC12574578

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.